Corporate Update on the Cigna Group’s 2025 Performance and Outlook
2025 Financial Performance
On 29 June 2026, the Cigna Group announced its financial results for the year ended 31 December 2025. The group’s earnings before interest, tax, depreciation and amortisation (EBITDA) declined modestly compared with the prior year. Management attributed the dip primarily to a reduced harvest of fresh fruit bunches (FFB) during the second half of 2025.
Despite this shortfall, the palm oil division benefited from higher market prices for crude palm oil (CPO) and palm kernel oil (PKO). The price premium helped offset the volume loss and supported revenue growth within that segment.
Cashew Processing Performance
In contrast, the cashew processing arm posted a notable improvement in operating performance. Enhanced raw cashew nut throughput combined with a favourable price environment for cashew nuts narrowed the 2025 loss to a marginal figure, a significant turnaround from the loss recorded in 2024.
Key drivers cited include the launch of a specialised unpeeled cashew product line and the ongoing expansion of processing capacity. These initiatives have positioned the cashew division to capture higher-value markets and to mitigate commodity price volatility.
Capital Structure and Liquidity Management
The board reiterated its strategy of reducing overall leverage through a mix of debt restructuring, equity injections, and refinancing of long‑term borrowings. Recent actions include the extension of several loans on favourable terms and the completion of a new bond programme that has already raised a substantial tranche.
Year‑end cash balances have strengthened, reflecting the group’s focus on liquidity and prudent financial management.
Outlook and Strategic Priorities
Management remains optimistic about the rebound in palm oil production expected in early 2026, alongside continued growth in the cashew operation. These developments are projected to lift the group’s earnings profile.
The board also disclosed ongoing evaluation of additional corporate finance opportunities to support expansion plans and optimise shareholder value. This includes potential equity issuances, strategic partnerships, and targeted acquisitions within complementary segments of the agri‑processing value chain.
Conclusion
The Cigna Group’s 2025 results demonstrate resilience amid commodity price swings and operational challenges. By combining disciplined capital management with focused investment in high‑margin product lines, the company is positioned to capitalize on recovery in key commodity markets and to deliver sustained value to shareholders.
